Intraarterial chemotherapy in China typically costs from $4,500 to $9,000. The total expense depends on the specific drug regimen, the number of cycles required, and the hospital tier. In the US, similar procedures cost around $40,000 on average. Patients save around 83% compared to US rates. The cost usually covers the procedure, medical team fees, and essential inpatient care during the infusion.
Bookimed Expert Insight: China offers access to world-class interventional oncology at costs approximately 60-70% lower than Western Europe. Facilities like Fuda Cancer Hospital in Guangzhou are JCI-accredited and specialize in advanced techniques like NanoKnife. Choosing a clinic with high procedure volumes is a smart move for value. For instance, Uni-asia Cancer Hospital in Chengdu performs thousands of interventional procedures annually. Their experts, like Dr. Zhang Jinshan, pioneered many of these techniques in China. International patients also benefit from complimentary services like airport transfers and dedicated interpreters. This reduces the logistical burden while maintaining high clinical standards.
| China | Turkey | Austria | |
| Intraarterial chemotherapy | ≈ $4,500 | from $5,000 | ≈ $9,500 |
Day 1 - Arrival
Day 2 - Pre-Operation
Day 3 - Intraarterial Chemotherapy
Day 4 - Post-Operation
Week 1 - Rehabilitation
Week 2
Please note that each patient"s experience may vary depending on their individual health condition and the specifics of their treatment plan.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.